PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Prazepam→

Prazepam PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2955-38-6
Molecular formula
C19H17ClN2O
Molecular weight
324.8 g/mol
Drug class
Benzodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Prazepam is metabolised to active benzodiazepine metabolites, including nordazepam, which positively modulate GABAA receptor activity at the benzodiazepine binding site and enhance GABA-mediated neuronal inhibition.
Indications / reported uses
  • Short-term treatment of anxiety disorders in countries where prazepam remains authorised; long-term use is limited by tolerance, dependence, sedation and withdrawal risk

Sources: NLM MeSH — Prazepam · PubMed — Prazepam benzodiazepine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Prazepam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Prazepam Permitted Daily Exposure (PDE) report (the Prazepam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Prazepam Occupational Exposure Limit (OEL) report (the Prazepam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.